Joaquim Vives

List of Publications by Year in Descending Order

60 papers	996 citations	17 h-index	29 g-index
84 ext. papers	1,216 ext. citations	3.5 avg, IF	4.31 L-index

#	Paper	IF	Citations
60	A pilot study of circulating levels of TGF-β1 and TGF-β2 as biomarkers of bone healing in patients with non-hypertrophic pseudoarthrosis of long bones.. *Bone Reports*, **2022**, 16, 101157	2.6	
59	Advances in translational orthopaedic research with species-specific multipotent mesenchymal stromal cells derived from the umbilical cord. *Histology and Histopathology*, **2021**, 36, 19-30	1.4	0
58	SARS-CoV-2/COVID-19 pandemic: first wave, impact, response and lessons learnt in a fully integrated Regional Blood and Tissue Bank. A narrative report. *Blood Transfusion*, **2021**, 19, 158-167	3.6	4
57	Use of Multipotent Mesenchymal Stromal Cells, Fibrin, and Scaffolds in the Production of Clinical Grade Bone Tissue Engineering Products. *Methods in Molecular Biology*, **2021**, 2286, 251-261	1.4	2
56	Towards the standardization of methods of tissue processing for the isolation of mesenchymal stromal cells for clinical use. *Cytotechnology*, **2021**, 73, 1-10	2.2	2
55	Clinical effects of intrathecal administration of expanded Wharton jelly mesenchymal stromal cells in patients with chronic complete spinal cord injury: a randomized controlled study. *Cytotherapy*, **2021**, 23, 146-156	4.8	10
54	Derivation of Mesenchymal Stromal Cells from Ovine Umbilical Cord Wharton's Jelly. *Current Protocols*, **2021**, 1, e18		
53	Transitioning From Preclinical Evidence to Advanced Therapy Medicinal Product: A Spanish Experience. *Frontiers in Cardiovascular Medicine*, **2021**, 8, 604434	5.4	1
52	Evaluation of a cell-based osteogenic formulation compliant with good manufacturing practice for use in tissue engineering. *Molecular Biology Reports*, **2020**, 47, 5145-5154	2.8	0
51	Characterization of a Cytomegalovirus-Specific T Lymphocyte Product Obtained Through a Rapid and Scalable Production Process for Use in Adoptive Immunotherapy. *Frontiers in Immunology*, **2020**, 11, 271	8.4	6
50	The challenge of developing human 3D organoids into medicines. *Stem Cell Research and Therapy*, **2020**, 11, 72	8.3	13
49	Effect of Allogeneic Cell-Based Tissue-Engineered Treatments in a Sheep Osteonecrosis Model. *Tissue Engineering - Part A*, **2020**, 26, 993-1004	3.9	7
48	Beyond chimerism analysis: methods for tracking a new generation of cell-based medicines. *Bone Marrow Transplantation*, **2020**, 55, 1229-1239	4.4	2
47	Strategies for large-scale expansion of clinical-grade human multipotent mesenchymal stromal cells. *Biochemical Engineering Journal*, **2020**, 159, 107601	4.2	8
46	Cord blood-derived platelet concentrates as starting material for new therapeutic blood components prepared in a public cord blood bank: from product development to clinical application. *Blood Transfusion*, **2020**, 18, 208-216	3.6	2
45	First-in-human PeriCord cardiac bioimplant: Scalability and GMP manufacturing of an allogeneic engineered tissue graft. *EBioMedicine*, **2020**, 54, 102729	8.8	14
44	Randomized clinical trial: expanded autologous bone marrow mesenchymal cells combined with allogeneic bone tissue, compared with autologous iliac crest graft in lumbar fusion surgery. *Spine Journal*, **2020**, 20, 1899-1910	4	8

43	Compliance with Good Manufacturing Practice in the Assessment of Immunomodulation Potential of Clinical Grade Multipotent Mesenchymal Stromal Cells Derived from WhartonЂs Jelly. *Cells*, **2019**, 8,	7.9	15
42	HLA-DR expression in clinical-grade bone marrow-derived multipotent mesenchymal stromal cells: a two-site study. *Stem Cell Research and Therapy*, **2019**, 10, 164	8.3	21
41	Extracellular vesicles: Squeezing every drop of regenerative potential of umbilical cord blood. *Metabolism: Clinical and Experimental*, **2019**, 95, 102-104	12.7	4
40	Adapting Cord Blood Collection and Banking Standard Operating Procedures for HLA-Homozygous Induced Pluripotent Stem Cells Production and Banking for Clinical Application. *Journal of Clinical Medicine*, **2019**, 8,	5.1	10
39	Osteogenic commitment of WhartonЂs jelly mesenchymal stromal cells: mechanisms and implications for bioprocess development and clinical application. *Stem Cell Research and Therapy*, **2019**, 10, 356	8.3	8
38	Levels of IL-17F and IL-33 correlate with HLA-DR activation in clinical-grade human bone marrow-derived multipotent mesenchymal stromal cell expansion cultures. *Cytotherapy*, **2019**, 21, 32-40	4.8	13
37	Derivation of Multipotent Mesenchymal Stromal Cells from Ovine Bone Marrow. *Current Protocols in Stem Cell Biology*, **2018**, 44, 2B.9.1-2B.9.22	2.8	16
36	Optimisation of a potency assay for the assessment of immunomodulative potential of clinical grade multipotent mesenchymal stromal cells. *Cytotechnology*, **2018**, 70, 31-44	2.2	11
35	Clinical translation of a mesenchymal stromal cell-based therapy developed in a large animal model and two case studies of the treatment of atrophic pseudoarthrosis. *Journal of Tissue Engineering and Regenerative Medicine*, **2018**, 12, e532-e540	4.4	8
34	Multipotent Mesenchymal Stromal Cells From Bone Marrow for Current and Potential Clinical Applications **2018**,		6
33	Stability enhancement of clinical grade multipotent mesenchymal stromal cell-based products. *Journal of Translational Medicine*, **2018**, 16, 291	8.5	12
32	Mesenchymal stem cells for cardiac repair: are the actors ready for the clinical scenario?. *Stem Cell Research and Therapy*, **2017**, 8, 238	8.3	38
31	Assessment of biodistribution using mesenchymal stromal cells: Algorithm for study design and challenges in detection methodologies. *Cytotherapy*, **2017**, 19, 1060-1069	4.8	13
30	Toward the clinical use of circulating biomarkers predictive of bone union. *Biomarkers in Medicine*, **2017**, 11, 1125-1133	2.3	5
29	A reproducible method for the isolation and expansion of ovine mesenchymal stromal cells from bone marrow for use in regenerative medicine preclinical studies. *Journal of Tissue Engineering and Regenerative Medicine*, **2017**, 11, 3408-3416	4.4	16
28	Clinical-scale expansion of CD34 cord blood cells amplifies committed progenitors and rapid scid repopulation cells. *New Biotechnology*, **2017**, 35, 19-29	6.4	2
27	Design and validation of a consistent and reproducible manufacture process for the production of clinical-grade bone marrow-derived multipotent mesenchymal stromal cells. *Cytotherapy*, **2016**, 18, 1197-1208	4.8	31
26	Streamlining the qualification of computerized systems in GxP-compliant academic cell therapy facilities. *Cytotherapy*, **2016**, 18, 1237-9	4.8	3

25	Cartilage resurfacing potential of PLGA scaffolds loaded with autologous cells from cartilage, fat, and bone marrow in an ovine model of osteochondral focal defect. *Cytotechnology*, **2016**, 68, 907-19	2.2	26
24	Final results of a phase I-II trial using ex vivo expanded autologous Mesenchymal Stromal Cells for the treatment of osteoarthritis of the knee confirming safety and suggesting cartilage regeneration. *Knee*, **2016**, 23, 647-54	2.6	106
23	Evaluation of a cell-banking strategy for the production of clinical grade mesenchymal stromal cells from Wharton's jelly. *Cytotherapy*, **2016**, 18, 25-35	4.8	28
22	Qualification of computerized monitoring systems in a cell therapy facility compliant with the good manufacturing practices. *Regenerative Medicine*, **2016**, 11, 521-8	2.5	1
21	BHRF1 exerts an antiapoptotic effect and cell cycle arrest via Bcl-2 in murine hybridomas. *Journal of Biotechnology*, **2015**, 209, 58-67	3.7	9
20	Ex vivo production of red blood cells from human cord blood. *BMC Proceedings*, **2015**, 9, P67	2.3	2
19	Quality compliance in the development of cell-based medicines in non-pharma environments. *BMC Proceedings*, **2015**, 9, P29	2.3	3
18	Development of an advanced cell therapy product indicated for the treatment of gonarthrosis. *BMC Proceedings*, **2015**, 9,	2.3	4
17	Off-the-shelf mesenchymal stromal cells derived from umbilical cord tissue. *BMC Proceedings*, **2015**, 9, P65	2.3	78
16	Quality compliance in the shift from cell transplantation to cell therapy in non-pharma environments. *Cytotherapy*, **2015**, 17, 1009-14	4.8	29
15	An arthroscopic approach for the treatment of osteochondral focal defects with cell-free and cell-loaded PLGA scaffolds in sheep. *Cytotechnology*, **2014**, 66, 345-54	2.2	17
14	Use of a chronic model of articular cartilage and meniscal injury for the assessment of long-term effects after autologous mesenchymal stromal cell treatment in sheep. *New Biotechnology*, **2014**, 31, 492-8	6.4	44
13	Transitory improvement of articular cartilage characteristics after implantation of polylactide:polyglycolic acid (PLGA) scaffolds seeded with autologous mesenchymal stromal cells in a sheep model of critical-sized chondral defect. *Biotechnology Letters*, **2014**, 36, 2143-53	3	21
12	Treatment of femoral head osteonecrosis with advanced cell therapy in sheep. *Archives of Orthopaedic and Trauma Surgery*, **2012**, 132, 1611-8	3.6	21
11	Dissecting the Mechanism of Action of BHRF1 for the Protection Against Apoptosis in MAb-Producing Cell Lines **2012**, 61-65		
10	Non-immortalized human neural stem (NS) cells as a scalable platform for cellular assays. *Neurochemistry International*, **2011**, 59, 432-44	4.4	19
9	Rmst is a novel marker for the mouse ventral mesencephalic floor plate and the anterior dorsal midline cells. *PLoS ONE*, **2010**, 5, e8641	3.7	30
8	Expression of BHRF1 improves survival of murine hybridoma cultures in batch and continuous modes. *Applied Microbiology and Biotechnology*, **2009**, 83, 43-57	5.7	8

7	A mouse model for tracking nigrostriatal dopamine neuron axon growth. *Genesis*, **2008**, 46, 125-31	1.9	2
6	BHRF-1 as a Tool for Genetic Inhibition of Apoptotis in Hybridoma Cell Cultures **2007**, 355-361		
5	Effect of Antiapoptotic Genes Expression on Cell Growth and Monoclonal Antibody Productivity in a Hybridoma Cell Line **2005**, 111-113		
4	Generation of embryonic stem cells and transgenic mice expressing green fluorescence protein in midbrain dopaminergic neurons. *European Journal of Neuroscience*, **2004**, 19, 1133-40	3.5	146
3	Protective effect of viral homologues of bcl-2 on hybridoma cells under apoptosis-inducing conditions. *Biotechnology Progress*, **2003**, 19, 84-9	2.8	23
2	Metabolic engineering of apoptosis in cultured animal cells: implications for the biotechnology industry. *Metabolic Engineering*, **2003**, 5, 124-32	9.7	38
1	The protection of hybridoma cells from apoptosis by caspase inhibition allows culture recovery when exposed to non-inducing conditions. *Journal of Biotechnology*, **2002**, 95, 205-14	3.7	27